Baby

CDC Announces Release of Over 77,000 Additional Doses of Beyfortusâ„¢ for RSV Protection in Infants

The Centers for Disease Control and Prevention (CDC) has recently announced the release of more than 77,000 additional doses of Beyfortusâ„¢ (nirsevimab-alip (100 mg)), a long-acting monoclonal antibody designed to …

CDC Announces Release of Over 77,000 Additional Doses of Beyfortusâ„¢ for RSV Protection in Infants Read More


Teleflex Incorporated

Teleflex Launches ACCESS-MANTA Registry to Evaluate MANTA Vascular Closure Device

WAYNE, PA — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced the first patient enrollment in the ACCESS-MANTAâ„¢ Registry. This international, multicenter, prospective, observational, single-arm …

Teleflex Launches ACCESS-MANTA Registry to Evaluate MANTA Vascular Closure Device Read More
Teleflex Incorporated

New Study Reinforces UroLiftâ„¢ System as Gold Standard Treatment for Enlarged Prostate

WAYNE, PA — A groundbreaking study published in the Nature journal Prostate Cancer and Prostatic Diseases has bolstered the position of the UroLiftâ„¢ System as the leading minimally invasive surgical …

New Study Reinforces UroLiftâ„¢ System as Gold Standard Treatment for Enlarged Prostate Read More

Aclaris Therapeutics

Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …

Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint Read More
National Comprehensive Cancer Network

New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect

PLYMOUTH MEETING, PA — New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more …

New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect Read More